Reata Pharmaceuticals recently announced the recruitment of the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in their Phase 2 LARIAT clinical trial evaluating the efficacy, safety, and tolerability of experimental therapy bardoxolone methyl in the treatment of patients with pulmonary hypertension (PH). The recent enrollment is part of…
Reata Enrolls First Patient in Clinical Trial for ILD Associated Pulmonary Hypertension
https://www.youtube.com/watch?v=0WaqsUIclWY Dr. Martina Vašáková discusses the need to diagnose idiopathic pulmonary fibrosis (IPF) early. Learn more about IPF: https://bit.ly/1QiRmr3…
A new study reported that patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) often experience lung function decline, which furthers disease progression. The study, titled “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” was published in the journal…
Read the articles here: 1. Potential Therapy for IPF and Fatty Liver Disorders Shows Safety in Early Clinical Trial 2. Systemic Sclerosis Patients with ILD Being Asked to Participate in Phase 3 Study of OFEV 3. In PF Mice, Fibroblast Activation Protein Seen…
In a new study entitled “The matrix protein Fibulin-5 lies at the interface of tissue stiffness and inflammation in fibrosis,” an international team of scientists discovered a new protein – Fibulin-5 – involved in skin fibrosis, and with potential therapeutic implications in fibrosis in other organs, including…
Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “…
In a new study, clinicians propose a new treatment protocol without immunosuppressants or high-dose steroids to manage and treat acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF). The study, titled “Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach,” was published in the journal…
Boehringer Ingelheim recently announced the enrollment of the first patient in its Phase 3 clinical trial, called SENSCIS (Safety and Efficacy of Nintedanib in Systemic Sclerosis), evaluating the safety and efficacy of the company’s product nintedanib (OFEV) in patients with systemic sclerosis and interstitial lung disease. Systemic sclerosis is a…
10. “Esbriet’s Promise and Potential as a PF Therapy” Read full article here: https://bit.ly/1HX2qZt Read Top 10 Pulmonary Fibrosis Articles of 2015: https://bit.ly/1OuOHvG 9. “Tissue Engineering Grows New Lungs in Lab That Could Revolutionize IPF Treatment” Read full article here: https://bit.ly/1RPnfcB Read Top…
May the New Year bring you strength and hope! Happy Holidays! Read the latest news on Pulmonary Fibrosis: https://bit.ly/1lfMsiZ…
